nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—Blood pressure increased—Sorafenib—thyroid cancer	0.00502	0.0547	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Vandetanib—thyroid cancer	0.00334	0.0364	CcSEcCtD
Phenylpropanolamine—Vision blurred—Vandetanib—thyroid cancer	0.00307	0.0334	CcSEcCtD
Phenylpropanolamine—Tremor—Vandetanib—thyroid cancer	0.00305	0.0332	CcSEcCtD
Phenylpropanolamine—Anxiety—Vandetanib—thyroid cancer	0.00276	0.0301	CcSEcCtD
Phenylpropanolamine—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00247	0.00272	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—MINPP1—thyroid cancer	0.00247	0.00272	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—CALCA—thyroid cancer	0.00245	0.0027	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CALCB—thyroid cancer	0.00244	0.00269	CbGpPWpGaD
Phenylpropanolamine—Insomnia—Vandetanib—thyroid cancer	0.0024	0.0262	CcSEcCtD
Phenylpropanolamine—MAOA—Metabolism—HPGD—thyroid cancer	0.00238	0.00262	CbGpPWpGaD
Phenylpropanolamine—Dyspnoea—Vandetanib—thyroid cancer	0.00237	0.0258	CcSEcCtD
Phenylpropanolamine—Flushing—Sorafenib—thyroid cancer	0.00234	0.0255	CcSEcCtD
Phenylpropanolamine—DRD1—Signaling Pathways—TRIM33—thyroid cancer	0.00231	0.00255	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—PTCH1—thyroid cancer	0.00231	0.00254	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00229	0.00252	CbGpPWpGaD
Phenylpropanolamine—Constipation—Vandetanib—thyroid cancer	0.00227	0.0247	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Sorafenib—thyroid cancer	0.00225	0.0245	CcSEcCtD
Phenylpropanolamine—ADRA1A—AMPK Signaling—TP53—thyroid cancer	0.00222	0.00244	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PRKAR1A—thyroid cancer	0.00222	0.00244	CbGpPWpGaD
Phenylpropanolamine—Liver injury—Epirubicin—thyroid cancer	0.0022	0.024	CcSEcCtD
Phenylpropanolamine—ADRB1—Signaling Pathways—CALCB—thyroid cancer	0.00219	0.00242	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CALCB—thyroid cancer	0.00215	0.00236	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—PTCH1—thyroid cancer	0.00214	0.00236	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—SST—thyroid cancer	0.00211	0.00232	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—TSHR—thyroid cancer	0.00211	0.00232	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—BRAF—thyroid cancer	0.0021	0.00231	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NDUFA13—thyroid cancer	0.0021	0.00231	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TRIM33—thyroid cancer	0.00208	0.00229	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.00206	0.00227	CbGpPWpGaD
Phenylpropanolamine—Liver injury—Doxorubicin—thyroid cancer	0.00204	0.0222	CcSEcCtD
Phenylpropanolamine—ADRB2—Signaling Pathways—TRIM33—thyroid cancer	0.00203	0.00224	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00203	0.00224	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—CALCA—thyroid cancer	0.00203	0.00223	CbGpPWpGaD
Phenylpropanolamine—Dyskinesia—Epirubicin—thyroid cancer	0.00197	0.0215	CcSEcCtD
Phenylpropanolamine—ADRA2A—Metabolism—CHST14—thyroid cancer	0.00197	0.00217	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00197	0.00217	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—SST—thyroid cancer	0.00196	0.00216	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—BRAF—thyroid cancer	0.00195	0.00215	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00193	0.00212	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—TSHR—thyroid cancer	0.00191	0.00211	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—PTEN—thyroid cancer	0.0019	0.00209	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—TSHR—thyroid cancer	0.00189	0.00209	CbGpPWpGaD
Phenylpropanolamine—Coordination abnormal—Epirubicin—thyroid cancer	0.00189	0.0206	CcSEcCtD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—CALCA—thyroid cancer	0.00189	0.00208	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00188	0.00207	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—AMPK Signaling—AKT1—thyroid cancer	0.00187	0.00206	CbGpPWpGaD
Phenylpropanolamine—Hepatocellular injury—Epirubicin—thyroid cancer	0.00185	0.0202	CcSEcCtD
Phenylpropanolamine—CYP1A2—Biological oxidations—RXRA—thyroid cancer	0.00185	0.00204	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—TSHR—thyroid cancer	0.00185	0.00204	CbGpPWpGaD
Phenylpropanolamine—Dyskinesia—Doxorubicin—thyroid cancer	0.00183	0.0199	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CALCB—thyroid cancer	0.00178	0.00195	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.00177	0.00195	CbGpPWpGaD
Phenylpropanolamine—Dizziness—Vandetanib—thyroid cancer	0.00176	0.0191	CcSEcCtD
Phenylpropanolamine—Coordination abnormal—Doxorubicin—thyroid cancer	0.00175	0.019	CcSEcCtD
Phenylpropanolamine—ADRB1—Signaling by GPCR—TSHR—thyroid cancer	0.00172	0.00189	CbGpPWpGaD
Phenylpropanolamine—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00172	0.0187	CcSEcCtD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00171	0.00188	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00169	0.00186	CbGpPWpGaD
Phenylpropanolamine—Vomiting—Vandetanib—thyroid cancer	0.00169	0.0184	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TRIM33—thyroid cancer	0.00168	0.00185	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—TSHR—thyroid cancer	0.00168	0.00185	CbGpPWpGaD
Phenylpropanolamine—Rash—Vandetanib—thyroid cancer	0.00167	0.0182	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vandetanib—thyroid cancer	0.00167	0.0182	CcSEcCtD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00165	0.00182	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CALCB—thyroid cancer	0.00165	0.00182	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—SST—thyroid cancer	0.00164	0.0018	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—PTCH1—thyroid cancer	0.00163	0.00179	CbGpPWpGaD
Phenylpropanolamine—Dyspnoea—Sorafenib—thyroid cancer	0.0016	0.0174	CcSEcCtD
Phenylpropanolamine—ADRA2A—Metabolism—HPGD—thyroid cancer	0.00159	0.00175	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—CALCA—thyroid cancer	0.00158	0.00174	CbGpPWpGaD
Phenylpropanolamine—Nausea—Vandetanib—thyroid cancer	0.00158	0.0172	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TRIM33—thyroid cancer	0.00156	0.00172	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TCF7L1—thyroid cancer	0.00154	0.0017	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—TSHR—thyroid cancer	0.00153	0.00169	CbGpPWpGaD
Phenylpropanolamine—Constipation—Sorafenib—thyroid cancer	0.00153	0.0167	CcSEcCtD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.00151	0.00166	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—SST—thyroid cancer	0.00149	0.00164	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—SST—thyroid cancer	0.00147	0.00162	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—IFNA2—thyroid cancer	0.00147	0.00162	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—PTCH1—thyroid cancer	0.00146	0.00161	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—SST—thyroid cancer	0.00144	0.00159	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—CALCA—thyroid cancer	0.00143	0.00158	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—PTCH1—thyroid cancer	0.00143	0.00157	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—TSHR—thyroid cancer	0.00142	0.00157	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—CALCA—thyroid cancer	0.00142	0.00156	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—TSHR—thyroid cancer	0.00139	0.00153	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TCF7L1—thyroid cancer	0.00139	0.00153	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—CALCA—thyroid cancer	0.00139	0.00153	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00137	0.00151	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—TPR—thyroid cancer	0.00137	0.00151	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—MINPP1—thyroid cancer	0.00136	0.0015	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TCF7L1—thyroid cancer	0.00136	0.00149	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PRKAR1A—thyroid cancer	0.00134	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—SST—thyroid cancer	0.00134	0.00147	CbGpPWpGaD
Phenylpropanolamine—Hypersensitivity—Sorafenib—thyroid cancer	0.00132	0.0144	CcSEcCtD
Phenylpropanolamine—ADRB2—Signaling by GPCR—SST—thyroid cancer	0.00131	0.00144	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—TP53—thyroid cancer	0.0013	0.00143	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—CDK1—thyroid cancer	0.0013	0.00143	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—TSHR—thyroid cancer	0.00129	0.00142	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CALCA—thyroid cancer	0.00129	0.00142	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00127	0.0014	CbGpPWpGaD
Phenylpropanolamine—Ataxia—Epirubicin—thyroid cancer	0.00127	0.0138	CcSEcCtD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.00126	0.00139	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CALCA—thyroid cancer	0.00126	0.00139	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—SST—thyroid cancer	0.00119	0.00131	CbGpPWpGaD
Phenylpropanolamine—Dizziness—Sorafenib—thyroid cancer	0.00118	0.0129	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PTCH1—thyroid cancer	0.00118	0.0013	CbGpPWpGaD
Phenylpropanolamine—Ataxia—Doxorubicin—thyroid cancer	0.00117	0.0128	CcSEcCtD
Phenylpropanolamine—SLC6A3—Transmission across Chemical Synapses—HRAS—thyroid cancer	0.00117	0.00129	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.00117	0.00129	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CDK1—thyroid cancer	0.00117	0.00128	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NDUFA13—thyroid cancer	0.00116	0.00128	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CALCA—thyroid cancer	0.00115	0.00126	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CDK1—thyroid cancer	0.00114	0.00126	CbGpPWpGaD
Phenylpropanolamine—Vomiting—Sorafenib—thyroid cancer	0.00114	0.0124	CcSEcCtD
Phenylpropanolamine—DRD1—Signaling Pathways—TSHR—thyroid cancer	0.00113	0.00124	CbGpPWpGaD
Phenylpropanolamine—Rash—Sorafenib—thyroid cancer	0.00113	0.0123	CcSEcCtD
Phenylpropanolamine—Dermatitis—Sorafenib—thyroid cancer	0.00113	0.0123	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TCF7L1—thyroid cancer	0.00112	0.00124	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PRKAR1A—thyroid cancer	0.00111	0.00122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—SST—thyroid cancer	0.00111	0.00122	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PTCH1—thyroid cancer	0.0011	0.00121	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CHST14—thyroid cancer	0.00109	0.0012	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—SST—thyroid cancer	0.00108	0.00119	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CALCA—thyroid cancer	0.00107	0.00117	CbGpPWpGaD
Phenylpropanolamine—Nausea—Sorafenib—thyroid cancer	0.00106	0.0116	CcSEcCtD
Phenylpropanolamine—DRD1—Signaling Pathways—MEN1—thyroid cancer	0.00106	0.00117	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TCF7L1—thyroid cancer	0.00104	0.00115	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CALCA—thyroid cancer	0.00104	0.00115	CbGpPWpGaD
Phenylpropanolamine—Drowsiness—Epirubicin—thyroid cancer	0.00104	0.0113	CcSEcCtD
Phenylpropanolamine—MAOA—Metabolism—SLC5A5—thyroid cancer	0.00102	0.00113	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TSHR—thyroid cancer	0.00102	0.00112	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.00101	0.00111	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—SST—thyroid cancer	0.00101	0.00111	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000999	0.0011	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TSHR—thyroid cancer	0.000994	0.00109	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000978	0.00108	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CALCA—thyroid cancer	0.000968	0.00107	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—HRAS—thyroid cancer	0.000965	0.00106	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTCH1—thyroid cancer	0.000961	0.00106	CbGpPWpGaD
Phenylpropanolamine—Drowsiness—Doxorubicin—thyroid cancer	0.00096	0.0105	CcSEcCtD
Phenylpropanolamine—ADRB1—Signaling Pathways—MEN1—thyroid cancer	0.000955	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CDK1—thyroid cancer	0.000943	0.00104	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MEN1—thyroid cancer	0.000934	0.00103	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TPR—thyroid cancer	0.000913	0.00101	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PRKAR1A—thyroid cancer	0.000899	0.000989	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Neuronal System—HRAS—thyroid cancer	0.000897	0.000988	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SST—thyroid cancer	0.000879	0.000968	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HPGD—thyroid cancer	0.000878	0.000967	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CDK1—thyroid cancer	0.000876	0.000965	CbGpPWpGaD
Phenylpropanolamine—Flushing—Epirubicin—thyroid cancer	0.000864	0.00942	CcSEcCtD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTCH1—thyroid cancer	0.000864	0.000951	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—RXRA—thyroid cancer	0.00086	0.000947	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000855	0.000941	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CALCA—thyroid cancer	0.000846	0.000931	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTCH1—thyroid cancer	0.000845	0.00093	CbGpPWpGaD
Phenylpropanolamine—Arrhythmia—Epirubicin—thyroid cancer	0.000832	0.00907	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TSHR—thyroid cancer	0.000822	0.000905	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000809	0.00089	CbGpPWpGaD
Phenylpropanolamine—Flushing—Doxorubicin—thyroid cancer	0.0008	0.00872	CcSEcCtD
Phenylpropanolamine—Tension—Epirubicin—thyroid cancer	0.000796	0.00867	CcSEcCtD
Phenylpropanolamine—ADRB1—Signaling Pathways—SST—thyroid cancer	0.00079	0.00087	CbGpPWpGaD
Phenylpropanolamine—Nervousness—Epirubicin—thyroid cancer	0.000788	0.00858	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MEN1—thyroid cancer	0.000773	0.000851	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SST—thyroid cancer	0.000773	0.000851	CbGpPWpGaD
Phenylpropanolamine—Arrhythmia—Doxorubicin—thyroid cancer	0.00077	0.00839	CcSEcCtD
Phenylpropanolamine—DRD1—Signaling Pathways—CDK1—thyroid cancer	0.000766	0.000843	CbGpPWpGaD
Phenylpropanolamine—Vision blurred—Epirubicin—thyroid cancer	0.000764	0.00833	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TSHR—thyroid cancer	0.000764	0.000841	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CALCA—thyroid cancer	0.00076	0.000837	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000751	0.000827	CbGpPWpGaD
Phenylpropanolamine—Agitation—Epirubicin—thyroid cancer	0.000745	0.00812	CcSEcCtD
Phenylpropanolamine—ADRB2—Signaling Pathways—CALCA—thyroid cancer	0.000744	0.000819	CbGpPWpGaD
Phenylpropanolamine—Tension—Doxorubicin—thyroid cancer	0.000736	0.00802	CcSEcCtD
Phenylpropanolamine—Nervousness—Doxorubicin—thyroid cancer	0.000729	0.00794	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MEN1—thyroid cancer	0.000718	0.000791	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000712	0.000784	CbGpPWpGaD
Phenylpropanolamine—Vision blurred—Doxorubicin—thyroid cancer	0.000707	0.0077	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTCH1—thyroid cancer	0.000699	0.00077	CbGpPWpGaD
Phenylpropanolamine—Agitation—Doxorubicin—thyroid cancer	0.000689	0.00751	CcSEcCtD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDK1—thyroid cancer	0.000688	0.000758	CbGpPWpGaD
Phenylpropanolamine—Anxiety—Epirubicin—thyroid cancer	0.000688	0.0075	CcSEcCtD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	0.000686	0.000756	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—SLC5A5—thyroid cancer	0.000684	0.000753	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDK1—thyroid cancer	0.000673	0.000741	CbGpPWpGaD
Phenylpropanolamine—Confusional state—Epirubicin—thyroid cancer	0.000667	0.00727	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTCH1—thyroid cancer	0.000649	0.000715	CbGpPWpGaD
Phenylpropanolamine—Tachycardia—Epirubicin—thyroid cancer	0.000646	0.00704	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SST—thyroid cancer	0.000639	0.000704	CbGpPWpGaD
Phenylpropanolamine—Anxiety—Doxorubicin—thyroid cancer	0.000637	0.00694	CcSEcCtD
Phenylpropanolamine—Hypotension—Epirubicin—thyroid cancer	0.000618	0.00674	CcSEcCtD
Phenylpropanolamine—Confusional state—Doxorubicin—thyroid cancer	0.000617	0.00673	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CALCA—thyroid cancer	0.000615	0.000677	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NRG1—thyroid cancer	0.000615	0.000677	CbGpPWpGaD
Phenylpropanolamine—Insomnia—Epirubicin—thyroid cancer	0.000599	0.00652	CcSEcCtD
Phenylpropanolamine—Tachycardia—Doxorubicin—thyroid cancer	0.000598	0.00651	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SST—thyroid cancer	0.000594	0.000654	CbGpPWpGaD
Phenylpropanolamine—Dyspnoea—Epirubicin—thyroid cancer	0.00059	0.00643	CcSEcCtD
Phenylpropanolamine—Somnolence—Epirubicin—thyroid cancer	0.000588	0.00641	CcSEcCtD
Phenylpropanolamine—ADRA2A—Metabolism—RXRA—thyroid cancer	0.000574	0.000633	CbGpPWpGaD
Phenylpropanolamine—Hypotension—Doxorubicin—thyroid cancer	0.000572	0.00623	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CALCA—thyroid cancer	0.000572	0.000629	CbGpPWpGaD
Phenylpropanolamine—Constipation—Epirubicin—thyroid cancer	0.000566	0.00617	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDK1—thyroid cancer	0.000557	0.000613	CbGpPWpGaD
Phenylpropanolamine—Insomnia—Doxorubicin—thyroid cancer	0.000554	0.00603	CcSEcCtD
Phenylpropanolamine—ADRB1—Signaling Pathways—NRG1—thyroid cancer	0.000553	0.000608	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TERT—thyroid cancer	0.000552	0.000608	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—NRAS—thyroid cancer	0.000548	0.000603	CbGpPWpGaD
Phenylpropanolamine—Dyspnoea—Doxorubicin—thyroid cancer	0.000546	0.00595	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Epirubicin—thyroid cancer	0.000545	0.00594	CcSEcCtD
Phenylpropanolamine—Somnolence—Doxorubicin—thyroid cancer	0.000544	0.00593	CcSEcCtD
Phenylpropanolamine—MAOA—Metabolism—PPARG—thyroid cancer	0.000543	0.000598	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NRG1—thyroid cancer	0.000541	0.000595	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HIF1A—thyroid cancer	0.000528	0.000581	CbGpPWpGaD
Phenylpropanolamine—Constipation—Doxorubicin—thyroid cancer	0.000524	0.00571	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDK1—thyroid cancer	0.000517	0.00057	CbGpPWpGaD
Phenylpropanolamine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000505	0.0055	CcSEcCtD
Phenylpropanolamine—CYP1A2—Metabolism—TPR—thyroid cancer	0.000504	0.000555	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TERT—thyroid cancer	0.000496	0.000546	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	0.000496	0.000546	CbGpPWpGaD
Phenylpropanolamine—Hypersensitivity—Epirubicin—thyroid cancer	0.000488	0.00531	CcSEcCtD
Phenylpropanolamine—ADRB2—Signaling Pathways—TERT—thyroid cancer	0.000485	0.000534	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HIF1A—thyroid cancer	0.000474	0.000522	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—KRAS—thyroid cancer	0.000471	0.000519	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—NRAS—thyroid cancer	0.000465	0.000512	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HIF1A—thyroid cancer	0.000464	0.000511	CbGpPWpGaD
Phenylpropanolamine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000451	0.00492	CcSEcCtD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.00045	0.000495	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NRG1—thyroid cancer	0.000447	0.000492	CbGpPWpGaD
Phenylpropanolamine—Dizziness—Epirubicin—thyroid cancer	0.000438	0.00477	CcSEcCtD
Phenylpropanolamine—DRD1—Signaling Pathways—BRAF—thyroid cancer	0.000437	0.000481	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—thyroid cancer	0.000427	0.00047	CbGpPWpGaD
Phenylpropanolamine—Vomiting—Epirubicin—thyroid cancer	0.000421	0.00458	CcSEcCtD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—thyroid cancer	0.000419	0.000461	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—NRAS—thyroid cancer	0.000418	0.00046	CbGpPWpGaD
Phenylpropanolamine—Rash—Epirubicin—thyroid cancer	0.000417	0.00455	CcSEcCtD
Phenylpropanolamine—Dermatitis—Epirubicin—thyroid cancer	0.000417	0.00454	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRG1—thyroid cancer	0.000415	0.000457	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—NRAS—thyroid cancer	0.000409	0.00045	CbGpPWpGaD
Phenylpropanolamine—Dizziness—Doxorubicin—thyroid cancer	0.000405	0.00441	CcSEcCtD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TERT—thyroid cancer	0.000401	0.000442	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—HRAS—thyroid cancer	0.000401	0.000441	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—KRAS—thyroid cancer	0.0004	0.000441	CbGpPWpGaD
Phenylpropanolamine—Nausea—Epirubicin—thyroid cancer	0.000393	0.00428	CcSEcCtD
Phenylpropanolamine—ADRB1—Signaling Pathways—BRAF—thyroid cancer	0.000393	0.000433	CbGpPWpGaD
Phenylpropanolamine—Vomiting—Doxorubicin—thyroid cancer	0.000389	0.00424	CcSEcCtD
Phenylpropanolamine—Rash—Doxorubicin—thyroid cancer	0.000386	0.00421	CcSEcCtD
Phenylpropanolamine—Dermatitis—Doxorubicin—thyroid cancer	0.000386	0.0042	CcSEcCtD
Phenylpropanolamine—ADRB2—Signaling Pathways—BRAF—thyroid cancer	0.000384	0.000423	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	0.000384	0.000423	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	0.000377	0.000416	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TERT—thyroid cancer	0.000373	0.000411	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTEN—thyroid cancer	0.000372	0.00041	CbGpPWpGaD
Phenylpropanolamine—Nausea—Doxorubicin—thyroid cancer	0.000364	0.00396	CcSEcCtD
Phenylpropanolamine—ADRA2A—Metabolism—PPARG—thyroid cancer	0.000363	0.000399	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—KRAS—thyroid cancer	0.00036	0.000396	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	0.000357	0.000393	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—thyroid cancer	0.000354	0.000389	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000354	0.000389	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—KRAS—thyroid cancer	0.000352	0.000387	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HRAS—thyroid cancer	0.00034	0.000375	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	0.000338	0.000372	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—thyroid cancer	0.000331	0.000364	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCND1—thyroid cancer	0.000319	0.000351	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	0.000318	0.00035	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—RXRA—thyroid cancer	0.000317	0.000349	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	0.000314	0.000346	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000308	0.00034	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PTEN—thyroid cancer	0.000308	0.000339	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HRAS—thyroid cancer	0.000306	0.000337	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—thyroid cancer	0.0003	0.000331	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HRAS—thyroid cancer	0.000299	0.000329	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—thyroid cancer	0.000297	0.000327	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	0.000295	0.000325	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	0.000291	0.00032	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—thyroid cancer	0.000291	0.00032	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCND1—thyroid cancer	0.000287	0.000316	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—thyroid cancer	0.000285	0.000314	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCND1—thyroid cancer	0.00028	0.000309	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PTEN—thyroid cancer	0.000277	0.000305	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NRAS—thyroid cancer	0.000275	0.000302	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PTEN—thyroid cancer	0.000271	0.000298	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	0.00027	0.000298	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—thyroid cancer	0.00027	0.000297	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—thyroid cancer	0.000264	0.000291	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTEN—thyroid cancer	0.000249	0.000274	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	0.000247	0.000272	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NRAS—thyroid cancer	0.000247	0.000272	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NRAS—thyroid cancer	0.000242	0.000266	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	0.000241	0.000265	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KRAS—thyroid cancer	0.000236	0.00026	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	0.000232	0.000255	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	0.00023	0.000253	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	0.000224	0.000247	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	0.000224	0.000246	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	0.000218	0.000241	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	0.000216	0.000237	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—thyroid cancer	0.000215	0.000236	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KRAS—thyroid cancer	0.000213	0.000234	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—thyroid cancer	0.00021	0.000231	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	0.000208	0.000229	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KRAS—thyroid cancer	0.000208	0.000229	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	0.000203	0.000223	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HRAS—thyroid cancer	0.000201	0.000221	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PPARG—thyroid cancer	0.0002	0.00022	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	0.0002	0.00022	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—thyroid cancer	0.000189	0.000208	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	0.000186	0.000204	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—thyroid cancer	0.000185	0.000203	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HRAS—thyroid cancer	0.000181	0.000199	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—thyroid cancer	0.000177	0.000195	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HRAS—thyroid cancer	0.000177	0.000195	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	0.000172	0.000189	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	0.00016	0.000176	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—thyroid cancer	0.000159	0.000176	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—thyroid cancer	0.000158	0.000173	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—thyroid cancer	0.000156	0.000172	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—thyroid cancer	0.000153	0.000168	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	0.000146	0.000161	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—thyroid cancer	0.000143	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—thyroid cancer	0.000142	0.000156	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTEN—thyroid cancer	0.000137	0.000151	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	0.000136	0.00015	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	0.000129	0.000142	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	0.00012	0.000132	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—thyroid cancer	7.92e-05	8.72e-05	CbGpPWpGaD
